Moore DT - Search Results

1

Molecular Stratification of Clear Cell Renal Cell Carcinoma by Consensus Clustering Reveals Distinct Subtypes and Survival Patterns.

Brannon AR, Reddy A, Seiler M, Arreola A, Moore DT, Pruthi RS, Wallen EM, Nielsen ME, Liu H, Nathanson KL, Ljungberg B, Zhao H, Brooks JD, Ganesan S, Bhanot G, Rathmell WK. Brannon AR, et al. Among authors: moore dt. Genes Cancer. 2010 Feb 1;1(2):152-163. doi: 10.1177/1947601909359929. Genes Cancer. 2010. PMID: 20871783 Free PMC article.

2

Hand-assisted laparoscopic nephrectomy: prospective evaluation of the learning curve.

Gaston KE, Moore DT, Pruthi RS. Gaston KE, et al. Among authors: moore dt. J Urol. 2004 Jan;171(1):63-7. doi: 10.1097/01.ju.0000099400.50350.9b. J Urol. 2004. PMID: 14665845

3

A pilot study of use of the cyclooxygenase-2 inhibitor celecoxib in recurrent prostate cancer after definitive radiation therapy or radical prostatectomy.

Pruthi RS, Derksen JE, Moore D. Pruthi RS, et al. BJU Int. 2004 Feb;93(3):275-8. doi: 10.1111/j.1464-410x.2004.04601.x. BJU Int. 2004. PMID: 14764122 Clinical Trial.

4

Impact of race, age, income, and residence on prostate cancer knowledge, screening behavior, and health maintenance in siblings of patients with prostate cancer.

Pruthi RS, Tornehl C, Gaston K, Lee K, Moore D, Carson CC, Wallen EM. Pruthi RS, et al. Eur Urol. 2006 Jul;50(1):64-9. doi: 10.1016/j.eururo.2005.09.024. Epub 2005 Dec 12. Eur Urol. 2006. PMID: 16364537

5

Phase II trial of celecoxib in prostate-specific antigen recurrent prostate cancer after definitive radiation therapy or radical prostatectomy.

Pruthi RS, Derksen JE, Moore D, Carson CC, Grigson G, Watkins C, Wallen E. Pruthi RS, et al. Clin Cancer Res. 2006 Apr 1;12(7 Pt 1):2172-7. doi: 10.1158/1078-0432.CCR-05-2067. Clin Cancer Res. 2006. PMID: 16609031 Clinical Trial.

6

Characterization of biochemical recurrence after radical prostatectomy.

Molitierno J, Evans A, Mohler JL, Wallen E, Moore D, Pruthi RS. Molitierno J, et al. Urol Int. 2006;77(2):130-4. doi: 10.1159/000093906. Urol Int. 2006. PMID: 16888417

7

The use of erythropoietin in patients undergoing radical prostatectomy: effects on hematocrit, transfusion rates and quality of life.

Gaston KE, Kouba E, Moore DT, Pruthi RS. Gaston KE, et al. Among authors: moore dt. Urol Int. 2006;77(3):211-5. doi: 10.1159/000094811. Urol Int. 2006. PMID: 17033207 Clinical Trial.

8

A prospective evaluation of the short-term impact and recovery of health-related quality of life in men undergoing radical prostatectomy.

Kouba E, Hubbard JS, Moore D, Wallen EM, Pruthi RS. Kouba E, et al. BJU Int. 2007 Jan;99(1):72-6. doi: 10.1111/j.1464-410X.2007.06533.x. BJU Int. 2007. PMID: 17227494

9

Neoadjuvant clinical trial with sorafenib for patients with stage II or higher renal cell carcinoma.

Cowey CL, Amin C, Pruthi RS, Wallen EM, Nielsen ME, Grigson G, Watkins C, Nance KV, Crane J, Jalkut M, Moore DT, Kim WY, Godley PA, Whang YE, Fielding JR, Rathmell WK. Cowey CL, et al. Among authors: moore dt. J Clin Oncol. 2010 Mar 20;28(9):1502-7. doi: 10.1200/JCO.2009.24.7759. Epub 2010 Feb 16. J Clin Oncol. 2010. PMID: 20159822 Free PMC article. Clinical Trial.

10

A phase II study of lapatinib, a dual EGFR and HER-2 tyrosine kinase inhibitor, in patients with castration-resistant prostate cancer.

Whang YE, Armstrong AJ, Rathmell WK, Godley PA, Kim WY, Pruthi RS, Wallen EM, Crane JM, Moore DT, Grigson G, Morris K, Watkins CP, George DJ. Whang YE, et al. Among authors: moore dt. Urol Oncol. 2013 Jan;31(1):82-6. doi: 10.1016/j.urolonc.2010.09.018. Epub 2011 Mar 10. Urol Oncol. 2013. PMID: 21396844 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

249 results

Search Page